UroGen Pharma (NASDAQ:URGN) Price Target Raised to $47.00

UroGen Pharma (NASDAQ:URGN) had its price objective upped by Scotiabank from $23.00 to $47.00 in a report issued on Friday,Benzinga reports. They currently have a sector outperform rating on the stock.

A number of other research analysts also recently commented on the company. Guggenheim boosted their price target on UroGen Pharma from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Friday. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. HC Wainwright cut UroGen Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 22nd. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Thursday. Finally, The Goldman Sachs Group decreased their target price on UroGen Pharma from $16.00 to $3.00 and set a “neutral” rating on the stock in a research report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, UroGen Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $28.71.

UroGen Pharma Stock Up 8.6%

URGN stock opened at $12.03 on Friday. The company has a market cap of $554.67 million, a PE ratio of -3.82 and a beta of 0.40. The business has a 50-day simple moving average of $8.54 and a 200 day simple moving average of $10.07. UroGen Pharma has a 52 week low of $3.42 and a 52 week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Sell-side analysts anticipate that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling at UroGen Pharma

In other news, insider Mark Schoenberg sold 5,162 shares of the business’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the sale, the insider now directly owns 153,378 shares in the company, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 5.10% of the company’s stock.

Institutional Trading of UroGen Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of UroGen Pharma by 4.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock worth $231,000 after purchasing an additional 969 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of UroGen Pharma by 0.8% during the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company’s stock worth $1,638,000 after purchasing an additional 1,125 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of UroGen Pharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after purchasing an additional 1,402 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of UroGen Pharma by 13.6% during the fourth quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock worth $242,000 after purchasing an additional 2,727 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of UroGen Pharma by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock worth $996,000 after purchasing an additional 3,024 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.